Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System.
Luisa M CardenasSunita GhoshAntonio FinelliLori WoodChristian K KollmannsbergerNaveen S BasappaJeffrey GrahamDaniel HengGeorg BjarnasonDenis SoulieresDominick BosseVincent CastonguayRamy SalehSimon TanguayBimal BhindiRodney H BreauFrédéric PouliotAly-Khan A LalaniPublished in: JCO global oncology (2023)
In Canada's publicly funded health care system, availability of standard mRCC therapies broadly reflects access from government-funded clinical trials and compassionate access program sources. In an evolving therapeutic landscape, ongoing advocacy is required to continue to facilitate patient access to efficacious therapies.